The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders--a double-blind placebo-controlled study.

Abstract

The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders was evaluated in a randomized, placebo-controlled study involving 40 patients. The intended study period was 18 months. The results showed zimeldine to be significantly more effective than placebo, both in terms of preventing recurrence (t-test: P less than 0.001) and the withdrawal rate (Cox's test: P less than 0.01). Adverse symptoms for zimeldine did not differ from placebo. There were no noteworthy changes in clinical chemistry, blood pressure, ECG and pulse rate.

• Authors: K Björk
• Journal: Acta psychiatrica Scandinavica. Supplementum (Acta Psychiatr Scand Suppl) Vol. 308 Pg. 182-9 ( 1983) ISSN: 0065-1591 [Print] Denmark
• PMID: 6230892 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Zimeldine

Topics

• Adult
• Aged
• Bipolar Disorder (prevention & control)
• Clinical Trials as Topic
• Depressive Disorder (prevention & control)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Patient Compliance
• Recurrence
• Zimeldine (adverse effects, therapeutic use)